These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 12868183)

  • 1. [Place of consensus type interferon alpha in the management of chronic type C hepatitis].
    Juszczyk J
    Pol Merkur Lekarski; 2003 Apr; 14(82):275-8. PubMed ID: 12868183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How to avoid discontinuation of ribavirin in combination with interferon to maintain efficacy of treatment for chronic hepatitis C patients.
    Kasahara A
    J Gastroenterol; 2004 Nov; 39(11):1125-6. PubMed ID: 15580413
    [No Abstract]   [Full Text] [Related]  

  • 3. [Interferon-alpha and ribavirin: advances in the therapy of chronic hepatitis C].
    Zeuzem S
    Dtsch Med Wochenschr; 1999 May; 124(20):636-42. PubMed ID: 10370387
    [No Abstract]   [Full Text] [Related]  

  • 4. Peginterferon alpha-2a (40 KD) plus ribavirin for the treatment of chronic hepatitis C in Japanese patients.
    Kuboki M; Iino S; Okuno T; Omata M; Kiyosawa K; Kumada H; Hayashi N; Sakai T
    J Gastroenterol Hepatol; 2007 May; 22(5):645-52. PubMed ID: 17444850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon and ribavirin treatment for chronic hepatitis C may activate celiac disease.
    Adinolfi LE; Durante Mangoni E; Andreana A
    Am J Gastroenterol; 2001 Feb; 96(2):607-8. PubMed ID: 11232725
    [No Abstract]   [Full Text] [Related]  

  • 6. Diabetic ketoacidosis induced by alpha interferon and ribavirin treatment in a patient with hepatitis C.
    Bhatti A; McGarrity TJ; Gabbay R
    Am J Gastroenterol; 2001 Feb; 96(2):604-5. PubMed ID: 11232722
    [No Abstract]   [Full Text] [Related]  

  • 7. Interstitial pneumonia recurrence during chronic hepatitis C treatment.
    Renou C; Germain S; Harafa A; Martin S; Larroque O; Muller P; Bertrand JJ; Halfon P
    Am J Gastroenterol; 2005 Jul; 100(7):1625-6. PubMed ID: 15984999
    [No Abstract]   [Full Text] [Related]  

  • 8. Development of reversible diabetes mellitus after cessation of interferon-alpha therapy for chronic hepatitis C infection.
    Tasi TN; Hsieh CH
    N Z Med J; 2004 Dec; 117(1207):U1230. PubMed ID: 15608817
    [No Abstract]   [Full Text] [Related]  

  • 9. Peginterferon and ribavirin for chronic hepatitis C.
    Hoofnagle JH; Seeff LB
    N Engl J Med; 2006 Dec; 355(23):2444-51. PubMed ID: 17151366
    [No Abstract]   [Full Text] [Related]  

  • 10. [Cutaneous reactions induced by pegylated-interferon plus ribavirin combination therapy in a patient with chronic hepatitis C].
    Enjoji M; Dainichi T; Gondo H; Urabe K
    Fukuoka Igaku Zasshi; 2007 Sep; 98(9):353-6. PubMed ID: 17974079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Combination therapy for chronic viral hepatitis C].
    Zeuzem S
    Dtsch Med Wochenschr; 2003 Feb; 128(8):370-4. PubMed ID: 12594622
    [No Abstract]   [Full Text] [Related]  

  • 12. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.
    McHutchison JG; Gordon SC; Schiff ER; Shiffman ML; Lee WM; Rustgi VK; Goodman ZD; Ling MH; Cort S; Albrecht JK
    N Engl J Med; 1998 Nov; 339(21):1485-92. PubMed ID: 9819446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cutaneous sarcoidosis associated with pegylated interferon alfa and ribavirin therapy in a patient with chronic hepatitis C.
    Rogers CJ; Romagosa R; Vincek V
    J Am Acad Dermatol; 2004 Apr; 50(4):649-50. PubMed ID: 15034524
    [No Abstract]   [Full Text] [Related]  

  • 14. [Treatment of chronic hepatitis C].
    Bell H; Dalgard O; Bjøro K; Hellum KB; Myrvang B
    Tidsskr Nor Laegeforen; 2002 Apr; 122(9):926-8. PubMed ID: 12082838
    [No Abstract]   [Full Text] [Related]  

  • 15. Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy.
    Sherman M; Yoshida EM; Deschenes M; Krajden M; Bain VG; Peltekian K; Anderson F; Kaita K; Simonyi S; Balshaw R; Lee SS;
    Gut; 2006 Nov; 55(11):1631-8. PubMed ID: 16709661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group.
    Davis GL; Esteban-Mur R; Rustgi V; Hoefs J; Gordon SC; Trepo C; Shiffman ML; Zeuzem S; Craxi A; Ling MH; Albrecht J
    N Engl J Med; 1998 Nov; 339(21):1493-9. PubMed ID: 9819447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alopecia universalis: a rare side effect seen on chronic hepatitis C treatment with peg-IFN and ribavirin.
    Demirturk N; Aykin N; Demirdal T; Cevik F
    Eur J Dermatol; 2006; 16(5):579-80. PubMed ID: 17101483
    [No Abstract]   [Full Text] [Related]  

  • 18. [New therapeutic possibilities in chronic hepatitis C].
    Criblez DH
    Praxis (Bern 1994); 2000 Mar; 89(11):450-3. PubMed ID: 10758732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination therapy for hepatitis C infection.
    Liang TJ
    N Engl J Med; 1998 Nov; 339(21):1549-50. PubMed ID: 9819457
    [No Abstract]   [Full Text] [Related]  

  • 20. Pegylated interferon: new preparation. Chronic hepatitis C: advantageous for some patients, but more data needed.
    Prescrire Int; 2003 Dec; 12(68):206-10. PubMed ID: 14986684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.